Why did HeartBeam (BEAT) stock go up? FDA designation, not clearance

What happened

HeartBeam closed Monday at about $0.65, up roughly 50% from Friday’s $0.43. About 404 million shares traded. Over the previous 30 sessions it averaged about 440,000 shares a day, so Monday’s volume was more than 900 times normal.

The stock opened at $0.75 and hit $0.95 before fading into the close.

The likely catalyst

At 8:31 a.m. ET, before the open, HeartBeam said the FDA had granted Breakthrough Device designation to the HeartBeam System as a tool for assessing potential heart attacks at home. Release.

Designation is not clearance. The program gives a device priority review and more contact with the FDA during development. It does not authorize the company to market the device for that use. FDA.

HeartBeam’s FDA clearances so far cover arrhythmia assessment. It plans to agree a multicenter pivotal study with the FDA and, if the study succeeds, to file to add heart attack assessment. Monday’s news is a step in that process. It is not an approval of an at-home heart attack test.

Money and dilution check

At 30 June, HeartBeam had $8.7 million of cash and equivalents, plus $57,000 of restricted cash. It used $7.0 million in operations in the first half. It said its cash was not enough for the next 12 months, which raises substantial doubt about its ability to continue as a going concern. It also said it expects no material commercial revenue in 2026. 10-Q.

Here is the financing record up to the cutoff:

• Older ATM with Public Ventures, LLC: up to $17 million at a 3% commission. HeartBeam sold 970,467 shares through it for $1.5 million net in early 2026, all before 11 March. 10-K.
• April offering: Titan Partners Group LLC, a division of American Capital Partners, underwrote 14.4 million shares at $0.80, including the over-allotment. 8-K.
• New ATM with Titan Partners Securities LLC, signed 14 August. It allows up to $25 million of share sales at a 3% commission. 8-K.

No filing says whether the Public Ventures agreement was ended when the Titan ATM was signed. No filing before Monday shows sales under the Titan ATM. The $25 million is a ceiling, not cash raised, and SEC size limits on smaller issuers can cap how much of it is usable. See the baby shelf rule.

HeartBeam also has a Nasdaq bid-price deficiency. The stock has been below $1, and the company has until 28 December to regain compliance. 8-K.

How we measured: regular-session close to close, from Alpaca Markets (SIP) daily bars, split-adjusted. Volume is compared with the average of the 30 trading sessions before the move.